Discover Viatris

Mylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life.

Although this Mylan site remains active for now, we encourage you to visit the Viatris site to learn more about our commitment to increasing access to quality medicines for patients when and where they need them.

Forging Partnerships

At a Glance

Working Together to Address Patient Needs

We work with tens of thousands of customers to make our products available to patients. Customers’ needs and expectations differ by market, depending on factors such as healthcare infrastructure, delivery systems, regulations, economic development and population. We strive to meet the needs of our customers regardless of the market type and aim to be their preferred partner.

Building Sustainable Supplier Relationships

Mylan relies on its suppliers to deliver high quality, affordable and accessible products to our customers and ultimately to patients. We have continued to build-out our Supplier Relationship Management program focusing on preferred suppliers to mitigate risk and enhance long term strategic partnerships. Our Supplier Relationship Management program aims to minimize risks by consolidating our supply base with preferred suppliers. Keeping good relationships helps not only to reduce risk and ensure a high quality and reliable supply but also helps us partner on our sustainability practices. 

We expect our suppliers to act in accordance with applicable laws, regulations and Mylan's Supplier Code of Conduct which provides guidance for doing business with Mylan. The Supplier Code of Conduct provides guidance for doing business with Mylan and supports our efforts to inspire, engage in and foster better health for a better world. Further, it aims to enhance supplier relationships and helps mitigate supply chain risks. We are committed to continually working to improve our operations and expect our business partners to promote similar principles throughout their supply chain.



Mitigating Supply Chain Risk

We have a robust due diligence process to better understand supplier capabilities and ensure their ability to comply with regulatory and compliance requirements. Our source selection process is governed by a Source Review Committee (SRC), comprised of a cross-functional  internal team from science, legal and sourcing. This team also manages the selection of API suppliers. Mylan has a proactive risk mitigation program to protect the supply chain by strengthening supply agreements with current suppliers and qualifying alternate suppliers. We monitor performance through reporting, trend analysis and consistent business review meetings. Mylan has established escalation and cross-functional issue management processes. Sourcing teams routinely meet with suppliers to review the performance of supply and create action plans to address identified risks. For our third-party finished dose formulation suppliers, we maintain an end-to-end product management approach.

Sustainable Supply Chain Management

Mylan’s vision for sustainable sourcing is to identify, evaluate and select goods and services across the globe that are strategically aligned with Mylan’s commitment to social and environmental responsibilities by fostering long-term relationships with suppliers that embrace sustainability practices.

Mylan’s Council for Sustainable Sourcing holds members of Mylan’s sourcing leadership team as well as members from Global Environmental Health and Safety, Commercial and Global Social Responsibility organizations. This group:

  • Provides guidance and direction for sustainable sourcing;
  • Develops policy, practice and reporting of sustainable sourcing;
  • Instills the culture of sustainable sourcing within sourcing teams;
  • Sets annual sustainable sourcing goals and objectives;
  • Develops, implements and monitors compliance of sustainable sourcing policies and metrics; and
  • Continues to expand our focus on Green Procurement.

In 2019, the sourcing team executed on commitments to support Mylan’s larger GSR efforts by continuing to build-out our sustainable sourcing program focused on the following areas:

  • Supplier Code of Conduct
  • Source selection
  • Partnerships and communication
  • Supplier diversity
  • Monitoring, reporting and continues improvements

Source selection is a key sourcing process to ensure vendors meet Mylan’s minimum standards for quality, cost and compliance. In 2019, we expanded our focus in this area to include:

  • Implementing an enhanced practice to consider  sustainability as part of the source selection process for direct materials. The new practice aims to verify that the  supplier has established sustainability program and has set sustainability goals.
  • Requiring vendor acknowledgement of Mylan’s Supplier Code of Conduct prior to new source selection or renewal of existing Supply Agreements for Direct Materials.

We also enhanced our standard Supply Agreement template to include sustainability language and clearer language on the right to request supporting documentation, the right to audit and implementation of corrective action plans as needed.
As part of our commitment to the AMR Industry Common Antibiotic Manufacturing Framework, we have notified our active antibiotic suppliers of our alignment with this Framework and expectations of  our suppliers.

Ensuring Good Partner Conduct

The Compliance department identifies business partner categories that may carry higher inherent risk. These partners, noted during the business contract drafting and approval process, are subject to a risk review depending on the aggregated risk factors assigned, as well as other Mylan compliance standards. Those identified as having an elevated risk are subject to a due diligence process including investigation and clarification of discovered legal, civil and reputational allegations or convictions. Any potentially high-risk business partners undergo a due diligence review and annual monitoring. Mylan also has a process to train business partners who interact with government officials on Mylan’s behalf on our Anti-Corruption Policy and procedures.

Innovating for Access

R&D supports the expansion of our portfolio to treat non-communicable and communicable conditions.

Our R&D work, while rooted in the development of traditional generic alternatives, now also focuses on complex generics, complex injectables, biosimilars and device-related activity to further impact outreach, compliance and access.

Additionally, we understand the value of collaboration to increase access and often work with others in the industry to develop new chemical entities (NCE) and repurposed molecules.

  • Lorem ipsum

    Lorem ipsum

  • Lorem ipsum

    Lorem ipsum

Loading the player...